Therefore, the approvals of EGFR inhibitors in non-small cell lung cancer (NSCLC) and CRC confirm the predicted dependence on EGFR signaling.53,54 In contrast, the low dependence of NSCLC on HGF signaling might explain the failure of Onartuzumab (MetMAb), a Met blocking antibody in a Phase 3 study in NSCLC.55 Similarly, EGFR inhibitors have not yet proven to result in clinical benefit in breast cancer,56 which is also in agreement with the predicted low EGF dependence of breast cancer. The gene discussed is HGF; the disease is non-small cell lung carcinoma.